癌症診斷市場：技術與事業相關趨勢及今後展望

Abstract

Cancer Diagnostics: Technology and Business Trends examines the current status of in vivo imaging applications and in vitro cancer diagnostic tests, as well as their future potential as important screening tools.

Cancer diagnostic technologies and assays are essential for the detection, diagnosis, and management of cancer. For certain cancers, methods are available for screening apparently healthy (asymptomatic) average-risk individuals. In addition, some cancers, such as cervical and colorectal cancers, can be detected in an even earlier, precancerous stage of development. For example, remote sample tests being developed by Epigenomics in partnership with Roche promise to identify more people with Stage I colorectal cancer and could dramatically decrease the mortality associated with this disease. These tests may enter the market as early as 2008/2009.

The diverse applications in cancer screening, monitoring, and diagnostics require a broad range of tools. Cancer Diagnostics: Technology and Business Trends profiles selected companies competing in this market to develop such technologies and apply them in novel and innovative ways. Topics evaluated in this report include the following:

• New molecular imaging technologies, such as positron emission tomography (PET).
• Advances in in vitro diagnostic colorectal cancer screening.
• Efforts to identify novel cancer biomarkers and develop new pharmacodiagnostic cancer tests.
• The field of pharmacodiagnostics--the development of tests to predict response to therapy or to identify the optimal therapy for a patient. Two examples of pharmacodiagnostic tests that are already being used--the DakoCytomation EGFR PharmDx test, and Immunophenotyping of leukemia and lymphoma--are discussed.
• Potential opportunities for DNA methylation tests.
• Market opportunities for current tests and emerging applications.

Table of Contents

CHAPTER 1

• BACKGROUND: TRENDS IN CANCER DIAGNOSTICS
  • 1.1. Summary of Key Trends
  • 1.2. Statistics Showing Impact of the Disease and the Need for Early Diagnosis
  • 1.3. Prospects for Cancer Theranostics

CHAPTER 2

• DEVELOPMENTS IN CANCER IMAGING
  • 2.1. Introduction
  • 2.2. Virtual Colonoscopy (Application of Computed Tomography in Colon Cancer Screening)
    • Description and Status
    • Potential Impact
    • Competition
    • Outlook
  • 2.3. Advances in Breast Cancer Imaging
    • Description and Status
    • Potential Impact
    • Competition
    • Outlook
  • 2.4. Emerging Role of Positron Emission Tomography in Cancer Diagnostics
    • Description and Status
    • Potential Impact
    • Competition
    • Outlook
  • 2.5. In Vivo Diagnostic Monoclonal Antibodies for Imaging Cancers
    • Description and Status
    • Potential Impact
    • Competition
    • Outlook

CHAPTER 3

• DEVELOPMENTS IN CANCER IN VITRO DIAGNOSTICS
  • 3.1. Introduction
    • “Traditional” Tumor Markers
    • Technologies Used for Cancer In Vitro Diagnostics
    • Trends in Cancer In Vitro Diagnostics
  • 3.2. Advances in In Vitro Diagnostic Colorectal Cancer Screening
    • Description and Status
    • Potential Impact
    • Competition
    • Outlook
  • 3.3. Theranostic Applications of Cancer In Vitro Diagnostics: Erbitux and EGFR
    • Description and Status
    • Potential Impact
    • Competition
    • Outlook
  • 3.4. Theranostic Applications of Cancer In Vitro Diagnostics: Applications in Leukemia and Lymphoma Diagnostics
    • Description and Status
    • Potential Impact
    • Competition
    • Outlook
  • 3.5. Changes in DNA Methylation: Application in Cancer Diagnostics
    • Description and Status
    • Potential Impact
    • Competition
    • Outlook
  • 3.6. Selected Advances in the Search for Novel Cancer Biomarkers/Tests

CHAPTER 4

• BUSINESS OUTLOOK
  • 4.1 Business Trends
    • Positron Emission Tomography
    • Breast Imaging: Mammography
    • In Vivo Diagnostic Monoclonal Antibodies
    • In Vitro Cancer Diagnostics
  • 4.2. Company Profiles
    • ABBOTT LABORATORIES
    • ADVANCED RESEARCH TECHNOLOGIES
    • APPLIED IMAGING
    • CARDINAL HEALTH
    • CELERA DIAGNOSTICS
    • CTI MOLECULAR IMAGING
    • DAKOCYTOMATION
    • EPIGENOMICS
    • EXACT SCIENCES
    • GE HEALTHCARE
    • NEOPROBE
    • ONCOMETHYLOME SCIENCES
    • PHILIPS MEDICAL SYSTEMS
    • ROCHE DIAGNOSTICS
    • SIEMENS MEDICAL SOLUTIONS

CHAPTER 5

• EXPERT INTERVIEWS
  • Roger Attick
  • David Bupp
  • Gary Schweikhardt
  • L. Blair Shamel
  • Daryl Sonnichsen, Pharm.D.

References

Glossary

Index